We are testing a new rifamycin solution for patients with mild to moderate left-sided ulcerative colitis. The study aims to see if it helps improve symptoms and induce remission compared to a placebo.
Health conditions and diseases that the clinical trial is designed to study and treat.
Left-sided ulcerative colitis is a form of inflammatory bowel disease that primarily affects the left side of the colon, leading to inflammation and ulceration. It can cause symptoms such as abdominal pain, diarrhea, and rectal bleeding.
These questions help us understand your situation so we can let the trial team know whether you might be a potential match. This is not a medical evaluation and is not part of the official screening, the study doctor will make the final decision..
Locations and medical facilities where this clinical trial is currently recruiting or conducting research. Select the locations where you would like to participate.
Disclaimer: Parts of this content have been automatically extracted from the EU Clinical Trials registry. While we strive for accuracy, please always contact the trial site or sponsor directly for correct and official information before making any decisions about participation. View on EU Clinical Trials.
